Extension of Time to File SOU

VYCEUM

Eli Lilly and Company

Request for Extension of Time to File a Statement of Use

PTO- 1581
Approved for use through 03/31/2024. OMB 0651-0054
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Request for Extension of Time to File a Statement of Use
(15 U.S.C. Section 1051(d))


The table below presents the data as entered.

Input Field
Entered
SERIAL NUMBER 90062733
LAW OFFICE ASSIGNED LAW OFFICE 115
MARK SECTION
MARK VYCEUM (see, http://uspto.report/TM/90062733/mark.png)
STANDARD CHARACTERS YES
USPTO-GENERATED IMAGE YES
LITERAL ELEMENT VYCEUM
OWNER SECTION (current)
NAME Eli Lilly and Company
MAILING ADDRESS Lilly Corporate Center
CITY Indianapolis
STATE Indiana
ZIP/POSTAL CODE 46285
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY United States
PHONE 317-651-1346
FAX 317 276 1919
EMAIL XXXX
OWNER SECTION (proposed)
NAME Eli Lilly and Company
MAILING ADDRESS Lilly Corporate Center
CITY Indianapolis
STATE Indiana
ZIP/POSTAL CODE 46285
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY United States
PHONE 317-651-1346
FAX 317 276 1919
EMAIL XXXX
CORRESPONDENCE INFORMATION (current)
NAME BRUCE W. LONGBOTTOM
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE trademarks@lilly.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) longbottom_bruce@lilly.com
CORRESPONDENCE INFORMATION (proposed)
NAME Bruce W. Longbottom
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE trademarks@lilly.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) longbottom_bruce@lilly.com
GOODS AND/OR SERVICES SECTION
INTERNATIONAL CLASS 005
CURRENT IDENTIFICATION Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases; Diagnostic agents, preparations and substances for medical purposes; diagnostic scanning agents for medical use, namely, diagnostic scanning agents for in vivo use; radiopharmaceutical diagnostic preparations for medical use; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative amyloid diseases
GOODS OR SERVICES KEEP ALL LISTED
EXTENSION SECTION
EXTENSION NUMBER 1
ALLOWANCE MAIL DATE 02/02/2021
STATEMENT OF USE NO
PAYMENT SECTION
NUMBER OF CLASSES 1
SUBTOTAL AMOUNT [EXTENSION FEE] 125
TOTAL AMOUNT 125
SIGNATURE SECTION
SIGNATURE /blongbottom/
SIGNATORY'S NAME Bruce W. Longbottom
SIGNATORY'S POSITION Assistant General Counsel
DATE SIGNED 06/30/2021
SIGNATORY'S PHONE NUMBER 317 651 1346
SIGNATURE METHOD Sent to third party for signature
FILING INFORMATION
SUBMIT DATE Wed Jun 30 15:48:14 ET 2021
TEAS STAMP USPTO/ESU-XX.XXX.XXX.XX-2
0210630154814743914-90062
733-780b3f5d37ae9b27bbfc7
9e1a9b5dfcfff582164c2350a
6f04692e7c4ba4723a41-DA-4
8124201-20210630113853948
657



PTO- 1581
Approved for use through 03/31/2024. OMB 0651-0054
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number


SOU Extension Request
(15 U.S.C. Section 1051(d))


To the Commissioner for Trademarks:

MARK: VYCEUM (see, http://uspto.report/TM/90062733/mark.png)
SERIAL NUMBER: 90062733

OWNER AND/OR ENTITY INFORMATION
The owner proposes to amend the following:
Current: Eli Lilly and Company, having an address of
      Lilly Corporate Center
      Indianapolis, Indiana 46285
      United States
      Phone: 317-651-1346
      Fax: 317 276 1919
      Email: XXXX
Proposed: Eli Lilly and Company, having an address of
      Lilly Corporate Center
      Indianapolis, Indiana 46285
      United States
      Phone: 317-651-1346
      Fax: 317 276 1919
      Email: XXXX

The owner requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application.    The Notice of Allowance mailing date was 02/02/2021.

For International Class 005:
Current identification: Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases; Diagnostic agents, preparations and substances for medical purposes; diagnostic scanning agents for medical use, namely, diagnostic scanning agents for in vivo use; radiopharmaceutical diagnostic preparations for medical use; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative amyloid diseases

For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this specific class.


This is the first extension request.

Correspondence Information (current):
      BRUCE W. LONGBOTTOM
      PRIMARY EMAIL FOR CORRESPONDENCE: trademarks@lilly.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): longbottom_bruce@lilly.com

Correspondence Information (proposed):
      Bruce W. Longbottom
      PRIMARY EMAIL FOR CORRESPONDENCE: trademarks@lilly.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): longbottom_bruce@lilly.com


Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the owner/holder and the owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).





A fee payment in the amount of $125 will be submitted with the form, representing payment for 1 class.


Declaration

STATEMENTS: The signatory believes that: the applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all the goods/services under Section 1(b) in the notice of allowance or as subsequently modified, or, if applicable, the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with all the goods/services/collective membership organization under Section 1(b) in the notice of allowance or as subsequently modified; and that to the best of the signatory's knowledge and belief, no other persons, except, if applicable, members and concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive.

DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any resulting registration, declares that all statements made of his/her own knowledge are true and that all statements made on information and belief are believed to be true.


Signature: /blongbottom/      Date Signed: 06/30/2021
Signatory's Name: Bruce W. Longbottom
Signatory's Position: Assistant General Counsel
Signatory's Phone: 317 651 1346
Signature method: Sent to third party for signature

PAYMENT: 90062733
PAYMENT DATE: 06/30/2021

Serial Number: 90062733
Internet Transmission Date: Wed Jun 30 15:48:14 ET 2021
TEAS Stamp: USPTO/ESU-XX.XXX.XXX.XX-2021063015481474
3914-90062733-780b3f5d37ae9b27bbfc79e1a9
b5dfcfff582164c2350a6f04692e7c4ba4723a41
-DA-48124201-20210630113853948657




uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed